Examining a stock’s 52-week price history, encompassing its low and high prices, can reveal much about its existing condition and potential future trajectory. Rigel Pharmaceuticals’s current trading price is 0.27% away from its 52-week high, while its distance from the 52-week low is 244.67%. The stock’s price range over this period has fluctuated between $12.00 and $41.25. The company, operating within the financial sector, had a trading volume of approximately 1.08 million for the day, which was noticeably higher than the average daily share volume of 0.37 million over the last 3 months.
Rigel Pharmaceuticals (RIGL) stock is currently valued at $41.36. During the last session, the stock experienced a remarkable rise, reaching $67.0 after opening at $41.36. The stock briefly dropped to $23.0 before ultimately closing at $38.94.
The market performance of Rigel Pharmaceuticals’s stock has been harmonious in recent times. Over the last year, the company’s stock reached its highest point at $41.25 on 08/20/25, while the lowest value for the same duration was $12.00 on 08/23/24.
Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis
Rigel Pharmaceuticals (RIGL) has experienced a quarterly rise of 105.57% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 741.89M and boasts a workforce of 164 employees.
Rigel Pharmaceuticals: What Analysts Are Saying
As of right now, 1 analyst is rating Rigel Pharmaceuticals as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 4 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Analyzing Trading Volume and Moving Average Trends
Based on Barchart.com data, the company’s moving average over the 100-day period was 21.04, with a change in price of +22.97. Similarly, Rigel Pharmaceuticals recorded 319,983 in trading volume during the last 100 days, posting a change of +124.90%.
Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis
The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for RIGL stands at 0.75. Similarly, the long-term debt-to-equity ratio is also 0.47.
RIGL Stock Stochastic Average
Today’s raw stochastic average for Rigel Pharmaceuticals over the last 50 days is 97.89%.This indicates a increase from the raw stochastic average of the past 20 days, which was 97.76%. Moreover, the company’s Stochastic %K and %D values for the last 20 days were 93.91% and 95.15%, respectively.
RIGL Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded an increase of 241.54%. However, over the last six months, the performance has been weaker by 100.58%. The price of RIGL increased 106.18% over the last 30 days. And in the last five days, it has surged by 13.07%.
